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Secretory Component: A New Role in Secretory
IgA-Mediated Immune Exclusion In Vivo
IgA units and the J chain are synthesized and assembled
by plasma cells, whereas SC is derived from the poly-
meric-Ig receptor (pIgR) that ensures selective trans-
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cytosis of IgAd/p across the epithelial cells of mucous1Unite´ de Pathoge´nie Microbienne Mole´culaire
membranes and exocrine glands (Mostov, 1994). ByINSERM U 389
serving as an external barrier, SIgA plays a major role2 Laboratoire de Technologie Cellulaire
in protecting mucosal surfaces against colonization andInstitut Pasteur
possible invasion by pathogenic microorganisms (Mes-28 rue du Dr Roux
tecky and McGhee, 1987; Kraehenbuhl and Neutra,F-75015 Paris
1992; Brandtzaeg, 1996; Corthe´sy and Kraehenbuhl,France
1999). Besides this so-called “immune exclusion” mech-3 ISREC
anism occurring at mucosal surfaces, evidence sug-Institut de Biochimie
gests that intracellular IgA translocated by the pIgR alsoChemin des Boveresses
plays a protective role by neutralizing virus replication1066 Epalinges
(Mazanec et al., 1993; Fujioka et al., 1998). In addition,4 CHUV-Lausanne
an IgA-mediated excretory pathway takes place in vivoDivision d’Immunologie et d’Allergie
to eliminate antigens present in tissues via binding toHoˆpital Orthope´dique
IgA and subsequent pIgR-mediated transport of the re-4 Avenue Pierre Decker
sulting immune complexes (Robinson et al., 2001).CH-1005 Lausanne
Although several reports have demonstrated the abil-Switzerland
ity of SC to enhance the stability of the antibody (Ab)
molecule in vitro (Lindh, 1975; Brown et al., 1970; Under-
down and Dorrington, 1974; Crottet and Corthe´sy, 1998),Summary
its possible function in the protective capacity of SIgA
in vivo remains elusive. In fact, the difficulty of producingSecretory immunoglobulin (Ig) A (SIgA) is essential in
sufficient amounts of purified IgA antibodies and theirprotecting mucosal surfaces. It is composed of at least
SIgA counterpart has precluded the strictly comparativetwo monomeric IgA molecules, covalently linked
analysis of their mechanism of action in in vivo models ofthrough the J chain, and secretory component (SC).
infection. Murine hybridoma cells secreting monoclonalWe show here that a dimeric/polymeric IgA (IgAd/p) is
IgAd/p (Michetti et al., 1992; Phalipon et al., 1995; Weltzinmore efficient when bound to SC in protecting mice
et al., 1996) as well as establishment of expression sys-against bacterial infection of the respiratory tract. We
tems producing milligrams of human recombinant SCdemonstrate that SC ensures, through its carbohy-
(rSC) with preserved IgAd/p binding capability (Rindis-drate residues, the appropriate tissue localization of
bacher et al., 1995) are tools that now allow this issueSIgA by anchoring the antibody to mucus lining the
to be addressed at the molecular level.epithelial surface. This in turn impacts the localization
In this study, we took advantage of the availabilityand the subsequent clearance of bacteria. Thus, SC
of such tools to compare, before and after its in vitro
is directly involved in the SIgA function in vivo. There-
association with rSC, the in vivo protective capacity of
fore, binding of IgAd/p to SC during the course of SIgA- a murine monoclonal IgAC5 specific for Shigella flexneri
mediated mucosal response constitutes a crucial step serotype 5a lipopolysaccharide (LPS) (Phalipon et al.,
in achieving efficient protection of the epithelial barrier 1995). S. flexneri, by triggering acute inflammation, is
by immune exclusion. the causative agent of shigellosis, an invasive disease
of the human colon (Philpott et al., 2000). Mice are not
Introduction susceptible to oral infection with Shigella. However,
when administered intranasally, shigellae invade the tra-
Mucosal surfaces are covered by epithelial cell layers cheo-bronchial and alveolar epithelia, leading to the de-
that form tight barriers separating a rapidly changing velopment of an acute tracheo-bronchitis and alveolitis
external environment from a highly regulated internal characterized by a massive influx of polymorphonuclear
compartment. The cellular barriers are vulnerable and the (PMN) cells. This inflammatory response in the lung tis-
integrity is ensured by the mucosal immune system that sue of mice mimics the acute inflammation observed in
provides specialized innate and adaptive defense mech- the intestinal mucosa of dysenteric patients (Mathan
anisms. The adaptive humoral local response is essentially and Mathan, 1991; Phalipon et al., 1995; Sansonetti et
mediated by SIgA which represents the major Ig found in al., 2000). We have previously shown that mice passively
mucosal secretions. It consists of two monomeric IgA administered via the nasal route with IgAC5 are pro-
units and two additional polypeptide chains, J chain and tected in a dose-dependent manner from subsequent
secretory component (SC) (Russell et al., 1999). The two intranasal infection; both tissue invasion and inflamma-
tion are markedly reduced in comparison to infected
mice not given IgAC5 (Phalipon et al., 1995). Based on5 Correspondence: phalipon@pasteur.fr
this background, we used a subprotective dose of IgAC56 Present address: Unite´ d’Histologie, Institut Pasteur, 28 rue du Dr
Roux, F-75015 Paris, France. to explore whether its association to rSC (rSC-IgAC5)
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Figure 1. Reconstitution of rSC-IgAC5 and
Analysis of Its Protective Effect In Vivo
(A) Purified rSC was visualized by silver stain-
ing following SDS-PAGE under reducing con-
ditions.
(B and C) IgAC5 before (B) and after (C) co-
valent association with rSC was visualized
following SDS-PAGE under nonreducing con-
ditions and Western blot analysis using anti-
chain, anti-J chain, and anti-SC antisera. Pos-
itive signals indicate proper assembly of the
IgAC5 and rSC-IgAC5 Ab molecules.
(D) Plot of lung bacterial load in mice given
specific (IgAC5, rSC-IgAC5) and control (IgA-
Sal4, rSC-IgASal4) mAbs, or PBS only prior
to bacterial challenge. The bacterial load in
the PBS group was fixed to 100 units.
or to deglycosylated rSC (rSCdg-IgAC5) modifies its pro- was reduced down to 20% in mice given rSC-IgAC5
(Figure 1D). Protection was specific for rSC-IgAC5 sincetective capacity in vivo. We show here that SC through
its glycosylated residues improves the protective ca- mice receiving the same amount of either rSC-Sal4 or
Sal4 alone, a monoclonal IgAd/p recognizing Salmonellapacity of IgAd/p by targeting the antibody to mucus, thus
achieving efficient blocking of bacterial infection by im- typhimurium LPS (Michetti et al., 1992), showed no re-
duction of the lung-bacterial load (Figure 1D). No de-mune exclusion.
crease in bacterial load was observed in mice given rSC
alone (data not shown). These results clearly indicateResults
that the enhanced protective capacity of rSC-IgAC5 re-
quires both IgAC5 specificity for S. flexneri LPS and itsThe Protective Capacity of IgAC5 Is Enhanced
association to rSC.upon Association with rSC
To investigate the role of SC in the protective capacity
of SIgA, we first mixed purified rSC (Figure 1A) with The Stability of IgAC5 In Vivo Is Not Improved
upon Association with rSCdimeric/polymeric IgAC5 comprising J chain (Figure 1B),
as previously described (Lu¨llau et al., 1996). Covalent We then determined whether the differential protection
observed using an equivalent amount of IgAC5 and rSC-association between the two partners was confirmed
by SDS-PAGE carried out under nonreducing conditions IgAC5 may reside in a different in vivo stability of the
two molecular forms of the antibody. Nonradiolabeledand Western blot using anti-SC antibodies (Figure 1C).
In our previous study demonstrating the protective ca- and [35S]Cys-labeled IgAC5 were mixed and then recon-
stituted or not with rSC. First, analysis of the radiola-pacity of IgAC5, mice were given 20g of IgAC5 intrana-
sally 1 hr prior to bacterial challenge with 107 cfu of S. beled molecules in bronchoalveolar lavages (BAL) re-
covered at 1 and 7 hr after intranasal administration offlexneri. The bacterial load in lung tissues measured at
6 hr postinfection was only 10% of that observed in the the antibodies was performed to determine the stability
at the time of bacterial challenge and 6 hr postinfection.control group (Phalipon et al., 1995). To compare the
neutralizing capacity of IgAC5 and rSC-IgAC5, we used Although more IgAp form was observed as compared to
IgAd in rSC-IgAC5 than in IgAC5, the pattern of nonin-the same experimental conditions except that the bacte-
rial challenge was performed with 108 cfu. Under these jected Ab was identical to that recovered at 1 and 7 hr
after mouse passive immunization (Figures 2A and 2B).conditions, the lung-bacterial load in IgAC5-treated
mice was 80% of that in the control group, whereas it Immunodetection using anti- chain and anti-SC anti-
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Figure 2. Stability of IgAC5 and rSC-IgAC5 In Vivo
Mice given intranasally a mixture of [35S]-Cys labeled and nonlabeled IgAC5 associated or nonassociated with rSC were sacrificed at 1 or 7
hr postinjection. Proteins in BAL were analyzed by SDS-PAGE under nonreducing conditions, followed by autoradiography (A and B). N.I.,
noninjected Ab preparations. (C) Immunodetection using anti- chain and anti-SC antisera at 1 and 7 hr in BAL of mice given IgAC5 and rSC-
IgAC5. Comparison of patterns with Figure 1C indicates stability of the molecules and preserved covalent association with rSC.
sera at 1 and 7 hr postinjection confirmed that IgAC5 was found in intimate contact with the epithelial surface
of the nasal cavity (Figure 3B). As expected (Herbertand rSC-IgAC5 assayed from 10 l of BAL displayed
identical bands, both in terms of intensity and overall and Leininger, 1999), using Alcian blue staining specific
for mucins, the nasal epithelium was found to be coveredpattern. Furthermore, covalent association with rSC was
preserved in the case of rSC-IgAC5 molecules (Figure by mucus lining (Figure 3C, arrows ). In the lungs, Micro-
Imager analysis revealed striking differences in the dis-2C). As the level of endogenous IgA recovered in BAL
of naive mice was barely detectable (data not shown), tribution of the two forms of the Ab molecule with IgAC5
diffusely distributed in lung tissue (Figure 4A), whereasthe IgA molecule visualized in Figure 2C corresponded
to the exogenous IgAC5 and rSC-IgAC5. Together, these rSC-IgAC5 accumulated in well-defined areas (Figure
4E). Autoradiography of the sections showed that IgAC5data indicate that the enhanced protective capacity of
IgAC5 upon its association to rSC is not reflected by an was found mainly in the alveoli (Figures 4B and 4C) in
which mucus was absent (Figure 4D), as expectedincreased in vivo stability of the reconstituted Ab.
(Dixon et al., 1999). In contrast, rSC-IgAC5 remained
associated with the bronchi (Figures 4F and 4G), in closeAssociation of IgAC5 with rSC Affects
Its Tissular Localization association with the epithelium (Figures 4H and 4I) that
was covered by a thin mucus lining (Figures 4J and 4K,As increased in vivo stability did not account for the
enhanced protective capacity of rSC-IgAC5, we exam- arrows), as previously documented (Dixon et al., 1999).
Note that due to incompatible protocols for autoradiog-ined whether a differential localization of the two forms
of the Ab at the time of bacterial challenge could explain raphy and staining, neighbor sections separated by 5
m were analyzed. Taken together, these data clearlythe difference observed in the protective capacity. Mice
were given [35S]Cys-labeled IgAC5 or rSC-[35S]Cys- demonstrate the involvement of rSC in establishing local
interactions with mucus that result in the peculiar tissuelabeled IgAC5 for 1 hr, and histological sections of nasal
cavity and lung tissue were examined using Micro- localization of the Ab molecule.
Imager analysis (Lanie`ce et al., 1998) followed by autora-
diography (Rougeot et al., 1997). In terms of localization Association of IgAC5 with rSC Modifies the Tissue
Localization of Bacteriain the nasal cavity, no significant difference was ob-
served between the two forms of the Ab molecule using We then examined whether the differential tissue local-
ization of the two forms of Ab influences the tissueMicro-Imager analysis (data not shown). However, fol-
lowing autoradiography of the same histological sec- localization of bacteria. Mice were given IgAC5 or rSC-
IgAC5 intranasally 1 hr prior to infection with GFP-tions, IgAC5 was shown to be mainly localized in the
lumen of the nasal cavity (Figure 3A) whereas rSC-IgAC5 expressing S. flexneri. The localization of fluorescent
Figure 3. Localization of IgAC5 and rSC-
IgAC5 into the Nasal Cavity at the Time of
Bacterial Challenge
Mice given intranasally [35S]-Cys-labeled
IgAC5 or rSC-IgAC5 were sacrificed at 1 hr
postinjection, heads were removed, and his-
tological sections were prepared.
(A and B) Photographic emulsions localizing
the tissular distribution of IgAC5 and rSC-
IgAC5 (magnification, 200).
(C) Mucus staining with arrows indicating the
mucus layer covering the nasal epithelium
(magnification, 100).
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Figure 4. Localization of IgAC5 and rSC-IgAC5 into the Lungs at the Time of Bacterial Challenge
Mice given intranasally [35S]-Cys-labeled IgAC5 or rSC-IgAC5 were sacrificed at 1 hr postinjection, and lungs were removed for histological
analysis. IgAC5 was used in experiments presented in (A)–(D). Experiments with rSC-IgAC5 are shown in (E)–(K). (A and E) Digital autoradiograms
obtained with a Micro-imager. (B, C, F, G, H, and I) Photographic emulsions; magnification, 200, except for (H) and (I), 400. (D, J, and K)
Mucus staining with Alcian blue; magnification, 400, except for (D), 200. Rectangles in (F) indicate the two areas magnified in (H) and (I),
respectively. Arrows point to binding of rSC-IgAC5 to the bronchial epithelium that is covered by the mucus layer. Note that due to incompatible
protocols for autoradiography and staining, serial histological sections of 5 m each have been used to show colocalization of the Ab with
mucus.
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Figure 5. In Vivo Localization of S. flexneri Bacteria in the Presence of IgAC5 or rSC-IgAC5
Mice given the Ab intranasally were infected 1 hr later by the same route using GFP-expressing S. flexneri. Localization of the fluorescent
bacteria was analyzed 6 hr postinfection using nasal cavity- and lung-histological sections of animals given PBS, IgAC5, and rSC-IgAC5.
Magnification, 100 for (A)–(E) and (E), and 200 for (F).
bacteria was observed 6 hr postinfection, using histo- tion in the differential localization and, therefore, in the
different protective capacities of IgAC5 and rSC-IgAC5,logical sections of both nasal cavity and lung. In the
absence of Ab, bacteria widely colonized the nasal mu- rSC was fully deglycosylated using N-Glycosidase F.
Following this treatment, rSCdg migrated as a doubletcosa and the lungs (Figures 5A and 5B). In the presence
of IgAC5, in comparison to mice not receiving the Ab, (Figure 6A), representing the two 60 and 66 kDa differen-
tially trimmed molecular forms of unglycosylated SCless bacteria were detected in the nasal cavity, but al-
most the same amount was present in lungs in accor- expressed in CHO cells (Rindisbacher et al., 1995). The
capacity of rSCdg to covalently associate with IgAC5dance with the slight decrease in the lung-bacterial load
shown in Figure 1. Nevertheless, bacteria invaded the was maintained (Figure 6B), and rSCdg-IgAC5 binding
to bacteria was similar to that of rSC-IgAC5 (data notepithelium of the nasal cavity (Figure 5C) and dissemi-
nated from the bronchi/bronchioli throughout the alveoli shown). The in vivo stability of rSCdg-IgAC5 was compa-
rable to that of rSC-IgAC5 (Figure 6C) and therefore to(Figure 5D), yet their distribution appeared restricted in
comparison to that observed in the control (Figure 5B). IgAC5 (Figure 2). However, rSCdg-IgAC5 was much less
efficient than rSC-IgAC5 in reducing the lung-bacterialConversely, in rSC-IgAC5-treated mice, fluorescent
bacteria were hardly detected, consistent with the 4-fold load (Figure 6D), resulting in a protection level compara-
ble to that of IgAC5 (Figure 1). Consistent with this, thedecrease in lung bacterial load shown in Figure 1. In
the nasal cavity, no intracellular bacteria were observed in vivo localization of rSCdg-IgAC5 resembled that of
IgAC5 (Figures 3A and 4B), i.e., lumenal in the nasal(Figure 5E), and only a few bacteria were seen as lumenal
aggregates (Figure 5E). In the lungs, the few bacteria cavity (Figure 6E) and diffusing from the bronchi/bron-
chioli to the alveoli (Figure 6F). These data demonstratedetected remained mainly localized within the bronchial
lumen (Figure 5F). These results demonstrate that the that the rSC carbohydrate residues mediate anchoring
of rSC-IgAC5 to mucus and are therefore responsibledifferential tissue distribution of the two forms of the Ab
molecule mediated by rSC binding to mucus has a direct for the in vivo localization of the Ab molecule, which
results in efficient protection by immune exclusion.effect on the number and localization of bacteria within
the infected tissues and therefore accounts for the dif-
ference observed in their respective protective capac- Discussion
ities.
We report here a previously unexpected role of SC in the
function of SIgA in vivo. We found that SC contributes toDeglycosylation of rSC Abrogates the Properties
Conferred by rSC to IgAC5 efficient SIgA-mediated protection by ensuring, through
its carbohydrate residues, the appropriate localizationHuman SC carries seven carbohydrate side chains
(Hughes et al., 1999), the function of which is thought of the Ab molecule, which therefore results in optimal
prevention of infection of mucosal surfaces by immuneto improve stability of the SIgA molecules. Sugar moie-
ties on SC have also been shown to be involved in the exclusion. This is a newly identified property of SC, in
addition to its role in protecting SIgA against proteolyticrecognition of glycoproteins (Boren et al., 1993; Dallas
and Rolfe, 1998) and in the prevention of bacterial adhe- degradation in the gastrointestinal tract (Crottet and
Corthe´sy, 1998) or the oral cavity (Ma et al., 1998) andsion to the epithelial surface (Giugliano et al., 1995;
Schroten et al., 1998). To assess the role of SC glycosyla- in neutralizing bacterial toxins or bacterial adhesion by
Immunity
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Figure 6. Deglycosylation of rSC and Func-
tional Properties of rSCdg-IgAC5
(A) Purified rSC treated () or not () with
N-endoglycosidase F (N-Glyc.F) run onto
SDS-PAGE and stained with Coomassie bril-
liant blue R.
(B) In vitro covalent reconstitution of rSCdg-
IgAC5; Western blot analysis using anti-SC
antiserum.
(C) In vivo stability of rSCdg-IgAC5 labeled
with (35S)-Cys at 1 and 7 hr postinjection. BAL
were analyzed by SDS-PAGE under nonre-
ducing conditions, followed by autoradiogra-
phy. N.I., noninjected material.
(D) Protective capacity of rSCdg-IgAC5; quan-
tification of the lung-bacterial load at 6 hr
postinfection in mice passively administered
with the Ab prior to intranasal bacterial chal-
lenge.
(E and F) Localization of rSCdg-IgAC5 in mice
given the Ab 1 hr prior to sacrifice; nasal cav-
ity and lung histological sections were pre-
pared (magnification, 200).
direct, nonspecific binding (Boren et al., 1993; Dallas and SC and Shigella occurs in the absence of specific Ag
recognition, it does not play a significant role in pro-Rolfe, 1998). Our results differ from the data reported
on the ability of different forms of the IgA molecule in tecting the host. However, we cannot exclude that Ab-
Ag interaction further promotes SC-bacteria interac-neutralizing virus infectivity in vitro that did not reveal
any specific contribution of SC to IgA function (Renegar tions, which in turn may contribute to the formation of
aggregates and thereby facilitate their elimination byet al., 1997). This can be explained by the fact that our
data clearly demonstrate the importance of the interac- mucociliary transport. Since we could not detect endog-
enous SC covalently associated with IgAC5 adminis-tions between the Ab and the local environment, which
cannot be mimicked in in vitro models. tered intranasally, SC present in bronchoalveolar lavage
(Merrill et al., 1980) does not permit conversion of muchWe show that the efficient protection mediated by
SIgA requires both IgA specificity and its association to IgAC5 into SC-IgAC5. This is further reflected by the
differential protection offered by the two forms of AbSC. No reduction in the lung bacterial load occurs in
the presence of rSC or rSC reconstituted with the control molecules. Therefore, the presence of SIgA covering
the mucosal surface in the respiratory tract is ensuredIgA. This suggests that, if direct interaction between
Role of SC in SIgA Function In Vivo
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essentially upon induction of local secretory responses of SC glycosylation in other functions attributed to SC
or upon passive administration of IgA already associ- such as activation of pulmonary eosinophils (Lamkhi-
ated with SC. oued et al., 1995; Motegi and Kita, 1998) and basophils
We demonstrate that SC does not significantly im- (Iikura et al., 1998) remains to be established. Further-
prove the IgA stability when the Ab molecule is present more, it will be interesting to examine whether the differ-
in the lower respiratory tract, whereas it has been shown ence reported here in the respiratory tract also exists
to protect the Ab molecule from proteolytic degradation at the gastrointestinal level.
in the gastrointestinal tract or oral cavity (Crottet and While keeping in mind that passively instilled SIgA
Corthe´sy, 1998; Ma et al., 1998). Taken together, these might not strictly behave like IgA transported physiologi-
results emphasize the influence of the local environment cally, the relevance of the data reported here has an
on the Ab stability with IgA being as stable as SIgA in important and immediate impact in the field of topical
a “sterile” environment as the lung in a healthy host but immunization. There has been a relative success for
less stable in the gastrointestinal tract where digestive topical Ab application (Zeitlin et al., 1999), in particular,
enzymes and the local flora represent a major source at the respiratory tract level (Weltzin and Monath, 1999)
of proteases. with Ab molecules delivered by nose drops or spray
Our results stress that in the respiratory tract SC sig- (Giraudi et al., 1997). However, despite the prevalence
nificantly contributes to protection because it influences of SIgA in mucosal secretions, most of the clinical trials
the in vivo localization of SIgA, which in turn affects have been performed by testing IgG or IgAd/p lacking
the bacterial localization. When SC is present, the Ab SC. Our data provide strong functional evidence that SC
molecule appears to be associated with mucus lining is crucial for secretory Ab to fulfill its optimal protective
the nasal mucosa and the bronchi, with no diffusion to function in vivo. Therefore, the molecular form of Ab to
the alveolar compartment. These results are consistent be delivered in order to achieve the best level of protec-
with the localization of SIgA in the vicinity of the mucosa, tion has to be reappraised. The results presented here
where they are generally trapped in the mucus upon support further clinical trials to assess the efficacy of in
induction of local responses in the respiratory tract vitro reconstituted SIgA in humans.
(Reynolds, 1991). In the infection model used, we ob- In summary, the use of in vitro reconstituted SIgA
serve that most of the bacteria are cleared in the pres- allowed us to explore the relationship existing between
ence of rSC-IgAC5. The remaining bacteria within the structure and function of SIgA in vivo. By comparing
nasal cavity are found as aggregates, and no bacteria protection conferred against bacterial infection using
are shown to invade the epithelium. Within the lung, naked IgAd/p or IgAd/p bound to SC, we revealed an intri-
the localization of the bacteria mimics that of the Ab guing role of SC in SIgA-mediated protection. In the
molecule, i.e., the bacteria accumulate in the lumen of course of SIgA production, binding of IgAd/p to SC upon
the bronchi. This demonstrates that SIgA, via SC ensur- pIgR-mediated transcytosis does not only allow the Ab
ing binding to mucus, forms a shield at the interface molecule to be secreted but also plays a key role in
between the invasive bacteria and the epithelial cells, providing efficient secretory antibodies by anchoring
thereby explaining their particular efficiency in mediat- them in mucus, thus ensuring immune exclusion at mu-
ing immune exclusion. On the other hand, in the absence cosal surfaces.
of SC, IgAC5 appears to be deprived of this capacity to
associate with mucus layer since it is found essentially Experimental Procedures
in the lumen of the nasal cavity and in the alveolar space.
Under these circumstances, bacteria are poorly elimi- Bacteria Strains
M90T, an invasive isolate of S. flexneri serotype 5a, and a transformantnated. This suggests that instead of being efficiently
expressing the green fluorescent protein (GFP) (Rathman et al., 2000)stopped and eliminated in the upper respiratory tract
were grown on trypticase soy broth (TCS, Diagnostics Pasteur,(i.e., nasal cavity) and in the tracheo-bronchial tract, the
Marnes la Coquette, France) at 37C with aeration. The bacteriabacteria can invade the epithelium of the nasal cavity
were washed and resuspended in PBS for mouse infections.
and further spread throughout the alveolar space. Con-
sequently, in the absence of SC, the lumenal localization Antibody Molecules
of the Ab molecule exhibits reduced potential for im- IgAC5 specific for S. flexneri serotype 5a LPS (Phalipon et al., 1995)
mune exclusion of the microorganisms. and Sal4 specific for Salmonella typhimurium LPS (Michetti et al.,
Another striking finding is that the carbohydrate resi- 1992) were purified from ascite fluids or after in vitro culture using
Celline-350 flasks (Integra-Biosciences).dues of SC are responsible for anchoring SIgA within
Expression vector pcDNA3:SC was created by inserting into XbaI/the mucus. Ab molecules are glycosylated at conserved
EcoRI-cut pcDNA3 plasmid (InVitrogen, Groningen, The Nether-positions in their constant regions, and the nature and
lands) the 1,85 kb fragment carrying the cDNA for human SC recov-
structure of carbohydrates have been shown to affect ered from XbaI/EcoRI-treated plasmid pBS-hSC:End (Rindisbacher
their function (Wright and Morrison, 1997). Association et al., 1995). Following transfection into CHO dhfr cells (CHO DUK;
of SIgA with the mucus layer has been documented, ATCC CRL 9096) and selection in the presence of G418, clones
for instance, in saliva where special mucins bind SIgA isolated by FACS scan were tested by ELISA (Rindisbacher et al.,
1995). The clone producing the highest amount of rSC represents(Biesbrock et al., 1991), but the role of SC in such an
the source of rSC used in the paper.interaction had not been addressed so far. Here, we
To obtain rSCdg, 500 g of rSC in 125 l of 50 mM sodium phos-demonstrate that SC plays such a role and that its glyco-
phate (pH 7.2) was combined with 15 units of N-Glycosidase F
sylated residues are required for the interaction. Further (Roche Molecular Diagnostics, Rotkreuz, Switzerland) in a silicon-
studies are needed to analyze whether a receptor spe- ized tube and incubated for 4 hr at 37C in a water bath.
cific for binding SIgA through the glycosylated residues N-Glycosidase F was removed by incubation for 1 hr with 20 l of
SP Sepharose bead slurry (Amersham Pharmacia Biotech, Zu¨rich,of SC is present in mucus. In addition, the involvement
Immunity
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Switzerland). Following gentle centrifugation, rSCdg was recovered ments. For rSCdg-IgAC5, 20 sections have been analyzed represent-
ing seven mice from two independent experiments.into the supernatant.
In vitro reconstitution of SIgA was performed by mixing an equi-
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